Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea: Reykjavik, Iceland Tuesday, June 24, 2025, 17:00 Hrs [IST] Alvotech, a global biot ...

Because the costs of aflibercept and ranibizumab are substantially higher than that of bevacizumab, an increasing number of insurers require step therapy, in which bevacizumab is used for the ...

Intraocular inflammation occurred more frequently with 8-mg aflibercept (Eylea) compared with what was observed in previous clinical trials among patients with neovascular age-related macular ...

89% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals through two years Of those assigned to a 16-week dosing regimen at baseline, 83% maintained ≥16-week dosing intervals ...

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

--Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application for aflibercept 8 mg for treatment ...

Eylea HD® (aflibercept) injection 8mg positive phase 3 results in patients with macular edema following retinal vein occlusion presented at Angiogenesis Meeting. News release.

New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema ‒ Post-hoc analyses from four Phase III studies indicate ...

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF ...